$9.07
+2.1%Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Strong working capital position provides significant operational flexibility and financial cushion.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
AVTR โข NYSE
| Avantor, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
365.4M | 261.9M | 262.9M | 372.9M | 301.7M | 286.6M | 186.7M | 184.7M | 185.4M | 62.9M | |
365.4M | 261.9M | 262.9M | 372.9M | 301.7M | 286.6M | 186.7M | 184.7M | 185.4M | 62.9M | |
1.1B | 1B | 1.2B | 1.2B | 1.2B | 1.1B | 988.8M | 931.2M | 875M | 87.9M | |
1.1B | 1B | 1.2B | 1.2B | 1.2B | 1.1B | 988.8M | 931.2M | 875M | 87.9M | |
818.2M | 731.5M | 828.1M | 913.5M | 872M | 739.6M | 711.2M | 671.1M | 695.1M | 122.2M | |
193M | 118.7M | 143.7M | 153.1M | 81.4M | 91.4M | 134.8M | 112.6M | 78.3M | 19M | |
2.5B | 2.1B | 2.4B | 2.7B | 2.5B | 2.2B | 2B | 1.9B | 1.8B | 292M | |
NON-CURRENT ASSETS | ||||||||||
766.8M | 708.1M | 737.5M | 727M | 705.5M | 549.9M | 557M | 598.6M | 663.5M | 204M | |
5B | 5.5B | 5.7B | 5.7B | 5.3B | 2.9B | 2.8B | 2.8B | 2.8B | 186.1M | |
3.2B | 3.4B | 3.8B | 4.1B | 5.1B | 4B | 4.2B | 4.6B | 5B | 441.4M | |
8.2B | 8.9B | 9.5B | 9.8B | 10.5B | 6.9B | 7B | 7.4B | 7.8B | 627.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1M | |
396M | 360.4M | 358.3M | 293.5M | 233.1M | 216.7M | 205.2M | 63M | 112.6M | 9.2M | |
9.3B | 10B | 10.6B | 10.8B | 11.4B | 7.7B | 7.8B | 8B | 8.6B | 843.8M | |
0.0 | 300K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
11.8B | 12.1B | 13B | 13.5B | 13.9B | 9.9B | 9.8B | 9.9B | 10.4B | 1.1B | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
741.7M | 662.8M | 625.9M | 758.2M | 755.1M | 678.9M | 560.2M | 557.4M | 542M | 58M | |
741.7M | 662.8M | 625.9M | 758.2M | 755.1M | 678.9M | 560.2M | 557.4M | 542M | 48M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10M | |
47.3M | 48.6M | 50.2M | 49.9M | 49.8M | 44.5M | 74.2M | 76.6M | 79M | 0.0 | |
30.8M | 821.1M | 259.9M | 364.2M | 45.2M | 26.4M | 93.5M | 142.4M | 109M | 13.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7M | 10M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10M | |
559.1M | 475M | 544.3M | 486.5M | 600.7M | 492.9M | 346.6M | 319.8M | 374.3M | 64.2M | |
1.4B | 2B | 1.5B | 1.7B | 1.5B | 1.2B | 1.1B | 1.1B | 1.1B | 135.9M | |
NON-CURRENT LIABILITIES | ||||||||||
3.9B | 3.2B | 5.3B | 5.9B | 7B | 4.9B | 5B | 6.8B | 7B | 1.3B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.9B | 3.6B | 0.0 | |
557.1M | 557.3M | 612.8M | 731.4M | 913M | 723.9M | 785.4M | 907.5M | 1.1B | 0.0 | |
378.2M | 358.3M | 350.3M | 295.4M | 358.4M | 398.1M | 428.2M | 4.2B | 3.9B | 228.1M | |
4.9B | 4.2B | 6.2B | 7B | 8.2B | 6B | 6.2B | 11.9B | 12B | 1.5B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 163M | 66.3M | 0.0 | 0.0 | |
6.2B | 6.2B | 7.7B | 8.6B | 9.7B | 7.2B | 7.3B | 13B | 13.1B | 1.6B | |
SHAREHOLDERS' EQUITY | ||||||||||
-75.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 1B | 1B | 1B | 3.9B | 3.6B | 338.8M | |
4B | 3.9B | 3.8B | 3.8B | 2.8B | 1.7B | 1.7B | 0.0 | 0.0 | 0.0 | |
1.7B | 2.2B | 1.5B | 1.2B | 483.9M | -88.7M | -203.7M | -238.4M | -156.3M | -5.7M | |
-16.9M | -184M | -69M | -100.3M | -43.2M | 21.7M | -85.9M | -66.5M | 26.4M | -30.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -6.6B | -6.1B | -677.6M | |
5.6B | 6B | 5.3B | 4.9B | 4.2B | 2.7B | 2.5B | -3.1B | -2.6B | -374.9M | |
5.6B | 6B | 5.3B | 4.9B | 4.2B | 2.7B | 2.5B | -3.1B | -2.6B | -510.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -135.7M | |
SUMMARY | ||||||||||
11.8B | 12.1B | 13B | 13.5B | 13.9B | 9.9B | 9.8B | 9.9B | 10.4B | 1.1B | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1M | |
3.9B | 4.1B | 5.5B | 6.3B | 7B | 4.9B | 5.1B | 6.9B | 7.1B | 1.3B | |
3.6B | 3.8B | 5.3B | 5.9B | 6.7B | 4.6B | 4.9B | 6.7B | 6.9B | 1.2B | |
681,814,859 | 681,814,859 | 681,814,859 | 681,814,859 | 681,814,859 | 681,814,859 | 681,814,859 | 681,814,859 | 681,814,859 | 681,814,859 |
AVTR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 12, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | March 26, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 27, 2026 | May 07, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | February 25, 2026 | December 17, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | February 25, 2026 | December 04, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 11, 2026 | December 31, 2025 | 2025 |
Continue your AVTR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.